Live Breaking News & Updates on Europe International At Jazz Pharmaceuticals

Stay updated with breaking news from Europe international at jazz pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Building begins on Cannabis-based Medicines Facility in UK

The recent initiation of construction of its new 60,000 sq ft manufacturing facility at Kent Science Park (KSP), in Sittingbourne UK, represents an investment of over $100 million (approximately £75m) by Jazz Pharmaceuticals plc and its subsidiary, GW Pharmaceuticals. Click to read more. ....

United Kingdom , Chris Tovey , Europe International At Jazz Pharmaceuticals , Jazz Pharmaceuticals , Gw Pharmaceuticals , Kent Science Park , Sittingbourne United Kingdom ,

Cannabidiol approved by Scottish Medicines Consortium

GW Pharmaceuticals, specialising in discovery and development of regulatory approved cannabis-based medicines, operating as a subsidiary of Dublin-based Jazz pharmaceuticals, has received confirmation that its Epidyolex® (cannabidiol) has been accepted by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older. Click to read more. ....

United Kingdom , Chris Tovey , Europe International At Jazz Pharmaceuticals , Tuberous Sclerosis Association , Wales Medicines Strategy Group , Healthcare Products Regulatory Agency , Scottish Medicines Consortium , Gw Pharmaceuticals , Dublin Based Jazz , All Wales Medicines Strategy Group , United Kingdom Medicines , Chief Executive ,